Today, Microsoft Corp announced that its highly popular email service, Outlook.com, is ready for prime time. Since the release of Outlook.com last summer as a preview, millions of people have already actively started using it, making it the world’s fastest growing email service, going from 0 to 60 million in just six months.
To view Multimedia News Release, go to http://www.multivu.com/pages/60076-microsoft-outlook-email-service
WebMD Health Corp. (Nasdaq: WBMD), the leading source of health information, announced today the launch of the WebMD Pregnancy app, a free iPhone® app offering expectant moms WebMD’s physician-reviewed pregnancy information that is customizable to fit a woman’s unique pregnancy. The WebMD Pregnancy App is WebMD’s latest addition to its multi-screen platform approach which provides actionable health information when consumers want it most, enabling them to better manage their health. WebMD is the leader in mobile for health information, with WebMD’s mobile apps for consumers having been downloaded over 16 million times.1
To view Multimedia News Release, go to http://www.multivu.com/mnr/60045-webmd-launches-new-pregnancy-app-for-iphone
1appFigures data through December 26, 2012; includes WebMD App, WebMD Baby App, WebMD Pain Coach App
Crosstex International, a subsidiary of Cantel Medical Corp. (NYSE:CMN), and Prestige Ameritech, the only two major U.S.-based medical mask manufacturers have joined forces to bring attention to a glaring void in public health research and policy – that, if addressed, has the potential to more quickly provide a simple, effective tool to mitigate the spread of influenza and other respiratory borne viruses. The awareness campaign comes in response to a new study, “ Exposure to Influenza Virus Aerosols During Routine Patient Care,” published in The Journal of Infectious Diseases, showing that influenza viruses may spread as far as six feet from a person coughing or sneezing, and that some people, referred to as “super spreaders,” may be more likely to spread the virus. The study, supported by the Department of Health and Human Services with a $600,000 research grant, pointed specifically to concerns for healthcare workers being exposed to coughs from sick patients. Yet government research and policy continues to overlook face masks as a feasible protection measure for both the healthcare industry and the general public.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60417-cantel-medical-fitted-mask-infectious-disease-control-public-health-policy
Kidde, the world’s largest manufacturer of fire safety products, has expanded its Worry-Free product line to include the first and only UL-listed carbon monoxide (CO) alarms proven to provide a decade of protection – up to twice the lifespan in other available alarms. Like the Kidde Worry-Free smoke alarms, the CO alarms contain a sealed-in lithium battery that powers the alarm and eliminates homeowners’ top fire safety complaint: a low-battery chirp. Kidde is a part of UTC Climate, Controls, & Security, a unit of United Technologies Corp. (NYSE: UTX).
To view Multimedia News Release, go to http://www.multivu.com/mnr/60977-kidde-worry-free-first-and-only-ul-listed-carbon-monoxide-co-alarms
Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61338-raptor-pharmaceutical-procysbi-fda-approval-nephropathic-cystinosis
WebMD Health Corp. (Nasdaq: WBMD), the leading source of health information, today announced the launch of its Health Care Reform Center (webmd.com/myhealthcare) for consumers and the ACA Resource Center for physicians (medscape.com/resource/aca), examples of our commitment to educate consumers and physicians and to provide actionable guidance about the impact of the Affordable Care Act (ACA). The Health Care Reform Center will include a series of live chats with experts, offering consumers personalized information to prepare for future health insurance decisions and navigate the health insurance marketplace at any stage of their journey—from young Americans who were previously uninsured to older Americans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60046-webmd-health-care-reform-center-consumer-physician-educational-website
SAIC, Inc. (NYSE: SAI) today held an Investor Day event in New York City in which the senior leadership team of the planned spin-off company, Science Applications International Corp. (SAIC), presented its business plans and financial objectives.
SAIC, Inc. previously announced plans to create two independent, publicly traded companies. Upon completion of the planned spin-off transaction, the technical, engineering and enterprise IT services business will retain the name SAIC and trade under (NYSE: SAIC), while the government and commercial solutions company will be named Leidos and trade under (NYSE: LDOS).
To view Multimedia News Release, go to http://www.multivu.com/mnr/63326-saic-presents-planned-company-s-business-financial-objectives-investor-day
WebMD Health Corp. (NASDAQ: WBMD), the leading source of health information, today announced at the mHealth Summit that it is expanding the beta program for its Patient Instructions feature, which enables physicians who use Medscape Mobile to securely send education and instructions on thousands of conditions, procedures and drugs to their patients who use the WebMD app for iPhone, or access WebMD on a PC or other mobile device. The company also previewed a forthcoming version of its WebMD app that leverages the 2net™ Platform from Qualcomm Life, Inc., a subsidiary of Qualcomm Incorporated (NASDAQ: QCOM), to enable health-conscious consumers to access and manage wireless health data from a wide array of fitness, wellness and medical devices directly from the app.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/60050-webmd-accelerates-consumer-provider-connectivity-personalized-mobile-app
WebMD Health Corp. (Nasdaq: WBMD), the leading source of health information, today released Marijuana on Main Street, a special report that provides an in-depth look at the debate over medical marijuana. As numerous states consider bills to legalize medical marijuana, WebMD surveyed nearly 3,000 consumers and Medscape surveyed more than 1,500 doctors about their attitudes regarding legalization, marijuana as a potential treatment option, and the perceived risks and benefits of its use to help shed light on this evolving issue.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7040258-webmd-medscape-medical-marijuana-report
Today, WebMD Health Corp. (NASDAQ: WBMD) launched WebMD Healthy Target, an integrated health improvement program that uses biometric device data from activity trackers, wireless scales and glucose meters to deliver tailored, physician-reviewed, contextually relevant content and motivational tips to individuals looking to develop sustainable health-conscious habits. WebMD Healthy Target will provide valuable assistance to individuals looking to manage chronic conditions like Type 2 diabetes and obesity, as well as to a broader audience interested in achieving their fitness goals or more generally living a healthier lifestyle.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/70402510-webmd-launches-health-improvement-program-for-iphone/
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7092251-fda-approve-s-exact-sciences-cologuard-screening-test-colorectal-cancer/
